← Back to Search

Human Amnion Membrane Allograft for Prostate Cancer Recovery (HAMMER Trial)

Phase 2
Recruiting
Led By Sanoj Punnen, MD, MAS
Research Sponsored by University of Miami
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men aged 40 to 80 years with localized prostate cancer who are undergoing bilateral nerve-sparing RARP at the University of Miami (UM)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 months, 6 months, 9 months, 12 months post-rarp
Awards & highlights

HAMMER Trial Summary

This trial looks at if a membrane can help men recover from prostate surgery faster by improving erectile function and urinary control.

Who is the study for?
This trial is for men aged 40 to 80 with localized prostate cancer, planning to have nerve-sparing robotic surgery at the University of Miami. It's not suitable for those who don't meet these specific age, health condition, and treatment location criteria.Check my eligibility
What is being tested?
The study is testing if a special placental tissue membrane (BioDFence G3) can help men recover faster from erectile dysfunction and urinary issues after their prostates are removed using robot-assisted surgery.See study design
What are the potential side effects?
Potential side effects may include reactions at the surgical site where the membrane is placed, such as infection or inflammation. However, detailed side effects will be monitored throughout the trial.

HAMMER Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man aged 40-80 with localized prostate cancer planning a specific surgery at UM.

HAMMER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 months, 6 months, 9 months, 12 months post-rarp
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 months, 6 months, 9 months, 12 months post-rarp for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Erectile Function Recovery as Measured by EPIC26 Sexual Domain Score
Secondary outcome measures
Change in Biochemical Failure
Change in Erectile Function Recovery as Measured by SHIM Score
Change in Proportion of Men with Mild ED or Better as Defined by EPIC26 Sexual Domain Score
+5 more

HAMMER Trial Design

2Treatment groups
Experimental Treatment
Group I: Membrane Arm: dHACM GroupExperimental Treatment2 Interventions
Participants will undergo standard of care robot-assisted radical prostatectomy (RARP) surgery and the dehydrated Human Amnion Chorion Membrane (dHACM) membrane placed after removal of the prostate. Participants will be in the group for approximately 12 months.
Group II: Control Arm: No dHACM GroupExperimental Treatment1 Intervention
Participants will undergo standard of care RARP surgery but will have no dehydrated Human Amnion Chorion Membrane (dHACM) placed after removal of the prostate. Participants will be in the group for approximately 12 months.

Find a Location

Who is running the clinical trial?

University of MiamiLead Sponsor
898 Previous Clinical Trials
409,411 Total Patients Enrolled
16 Trials studying Prostate Cancer
3,647 Patients Enrolled for Prostate Cancer
Integra LifeSciences CorporationIndustry Sponsor
84 Previous Clinical Trials
9,249 Total Patients Enrolled
1 Trials studying Prostate Cancer
Sanoj Punnen, MD, MASPrincipal InvestigatorUniversity of Miami
2 Previous Clinical Trials
507 Total Patients Enrolled
2 Trials studying Prostate Cancer
507 Patients Enrolled for Prostate Cancer

Media Library

Membrane Arm: dHACM Group Clinical Trial Eligibility Overview. Trial Name: NCT05842057 — Phase 2
Prostate Cancer Research Study Groups: Membrane Arm: dHACM Group, Control Arm: No dHACM Group
Prostate Cancer Clinical Trial 2023: Membrane Arm: dHACM Group Highlights & Side Effects. Trial Name: NCT05842057 — Phase 2
Membrane Arm: dHACM Group 2023 Treatment Timeline for Medical Study. Trial Name: NCT05842057 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment for this experiment still open?

"Data on clinicaltrials.gov reveals that this trial, first posted June 30th 2023 and most recently updated April 24th 2023, is no longer recruiting participants at this time. Fortunately, there are 887 other medical studies actively seeking volunteers presently."

Answered by AI

Is there an age cap for individuals wishing to participate in this research?

"Individuals 40 years of age and older, but younger than 80 are being sought for enrollment in this study."

Answered by AI

Could you please elaborate on the potential perils of Membrane Arm: dHACM Group to patients?

"Our team's assessment of the safety profile of Membrane Arm: dHACM Group is a 2, which implies that there exists some evidence supporting its safety but not any data indicating its efficacy."

Answered by AI

Could I participate in this research endeavor?

"In order to qualify for this trial, prostate cancer patients aged 40-80 are welcome. The total number of participants is expected to reach 240 individuals."

Answered by AI
~160 spots leftby Aug 2027